---
reference_id: "PMID:32327173"
title: ROS1-rearranged Non-small Cell Lung Cancer.
authors:
- Giustini NP
- Bazhenova L
journal: Thorac Surg Clin
year: '2020'
doi: 10.1016/j.thorsurg.2020.01.007
content_type: abstract_only
---

# ROS1-rearranged Non-small Cell Lung Cancer.
**Authors:** Giustini NP, Bazhenova L
**Journal:** Thorac Surg Clin (2020)
**DOI:** [10.1016/j.thorsurg.2020.01.007](https://doi.org/10.1016/j.thorsurg.2020.01.007)

## Content

1. Thorac Surg Clin. 2020 May;30(2):147-156. doi: 10.1016/j.thorsurg.2020.01.007.

ROS1-rearranged Non-small Cell Lung Cancer.

Giustini NP(1), Bazhenova L(2).

Author information:
(1)UCSD Moores Cancer Center, 3855 Health Sciences Drive #0829, La Jolla, CA 
92093-0829, USA.
(2)UCSD Moores Cancer Center, 3855 Health Sciences Drive MC #0987, La Jolla, CA 
92093-0829, USA. Electronic address: lbazhenova@health.ucsd.edu.

ROS1-rearranged non-small cell lung cancer (NSCLC) makes up approximately 1% to 
2% of all NSCLC, is oncogenically driven by a constitutively activated ROS1 
kinase paired with certain fusion partners, and can be detected by several 
different assays. These patients are initially treated with tyrosine kinase 
inhibitors (TKIs), which target the activated ROS1 kinase. Eventually these 
tumors develop resistance to initial TKI treatment through secondary kinase 
mutations that block TKI binding or activation of bypass signaling pathways, 
which subvert ROS1 as the driver of the malignancy. Investigation of several 
TKIs that have shown efficacy in secondary resistant patients is underway.

Copyright Â© 2020 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.thorsurg.2020.01.007
PMID: 32327173 [Indexed for MEDLINE]

Conflict of interest statement: Disclosure LB has received advisory board 
honoraria from the following companies in the past 12 months: Blueprint, Takeda, 
Astra Zeneca, Genentech, BeyondSpring Pharmaceuticals, G1 Therapeutics, 
Boehringer Ingelheim.